<?xml version="1.0" encoding="UTF-8"?>
<records>
<record>
<language>eng</language>
<publisher>Science and Education Publishing</publisher>
<journalTitle>American Journal of Medical Sciences and Medicine</journalTitle>
<eissn>2327-6657</eissn>
<publicationDate>2018-11-09</publicationDate>
<volume>6</volume>
<issue>2</issue>
<startPage>45</startPage>
<endPage>50</endPage>
<doi>10.12691/ajmsm-6-2-6</doi>
<publisherRecordId>AJMSM2018626</publisherRecordId>
<documentType>article</documentType>
<title language="eng">Liver Enzyme Abnormalities: A Comparative Study between Treatment Na&#239;ve HIV and HIV Negative Hospital Patients</title>
<authors>
<author>
<name>Ganiyat Oyeleke</name>
<email>drgoyeleke@yahoo.com</email>
<affiliationId>1</affiliationId>
</author>
<author>
<name>Anele Ihekwaba</name>
<affiliationId>2</affiliationId>
</author>

</authors>
<affiliationsList>
<affiliationName affiliationId="1">Lagos University Teaching Hospital, Lagos State, Nigeria</affiliationName>
<affiliationName affiliationId="2">University of Port Harcourt Teaching Hospital, Rivers State, Nigeria</affiliationName>
</affiliationsList>
<abstract language="eng">Background and Aims: The prevalence of People living with human Immunodeficiency virus remains considerably high in Nigeria. Liver disease has emerged as an increasingly significant contributor to mortality among HIV-infected patients. The aim of our study was to compare the difference in the prevalence of liver enzyme abnormalities between treatment na&#239;ve HIV positive and HIV negative patients. Method: The study was conducted at a teaching hospital. The study population consists of 736 patients (368 cases and 368 controls) that were selected from the hospital. The cases were treatment na&#239;ve HIV patients and the controls were patients being managed for other diseases. A diagnosis of liver disease was made based on the diagnostic criteria which include; presence of at least one clinical feature of liver disease, two liver chemistry abnormalities and an abnormal hepatic ultrasound report. Result: The mean ages of the cases and controls were 35.97&#177;9.77 and 36.08&#177;9.54 years respectively. Liver disease was seen in 277 (75.3%) of the cases and 54 (14.7%) of the controls, this difference was statistically significant (p&lt;0.001). Alkaline phosphatase ALP (p&lt;0.001) and Gamma-glutamyl transferase GGT (p=0.04) were indicative of the presence of liver diseases in univariate analysis. Although Bilirubin was not of statistical significance, all HIV infected patients with total bilirubin ≥ 25.5&#181;mol/L had liver diseases. Conclusion: The use of abnormal liver enzymes and clinical features in resource poor settings are valuable screening tools to indicate the presence of liver diseases particularly in HIV ݨC infected patients.</abstract>
<fullTextUrl format="pdf">http://pubs.sciepub.com/ajmsm/6/2/6/ajmsm-6-2-6.pdf</fullTextUrl>
<keywords language="eng"><keyword>liver enzyme abnormalities</keyword>
<keyword>HIV</keyword>
<keyword>treatment na?ve HIV patients</keyword>
<keyword>Nigeria</keyword>
</keywords>
</record>
</records>
